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Abstract: Linear regression models are often used to represent the cost and effectiveness 
of medical treatment. The covariates used may include sociodemographic variables, such 
as age, gender or race; clinical variables, such as initial health status, years of treatment or 
the  existence  of  concomitant  illnesses;  and  a  binary  variable  indicating  the  treatment 
received. However, most studies estimate only one model, which usually includes all the 
covariates. This procedure ignores the question of uncertainty in model selection. In this 
paper, we examine four alternative Bayesian variable selection methods that have been 
proposed. In this analysis, we estimate the inclusion probability of each covariate in the 
real  model  conditional  on  the  data.  Variable  selection  can  be  useful  for  estimating 
incremental effectiveness and incremental cost, through Bayesian model averaging, as well 
as for subgroup analysis. 
Keywords: variable selection; Bayesian analysis; cost-effectiveness; BIC; Intrinsic Bayes 
Factor; Fractional Bayes Factor; subgroup analysis 
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1. Introduction  
Econometric literature shows that modelling questions such as risk, resource use and the outcomes 
of alternative medical treatments is normally based on the use of covariates in regression models 
applied  to  microdata  [1-6].  Several  recent  papers  have  proposed  the  use  of  covariates  for  the 
comparison of technologies through cost-effectiveness analysis (CEA). Hoch et al. [7] were pioneers 
in this research, showing that the use of regression analysis could produce more accurate estimates of 
treatment  cost-effectiveness,  by  modelling  the  net  monetary  benefit  in  terms  of  covariates.  
Willan et al. [8] directly considered costs and effects jointly, assuming a bivariate normal distribution. 
Vá zquez-Polo et al. [9] used an asymmetric framework in which costs are accounted for by effects, but 
effects, on the other hand, are not affected by cost. In a subsequent work, Vá zquez-Polo et al. [10] 
proposed a general framework where effectiveness can be measured by means of a quantitative or a 
binary variable. In this study, costs were also analyzed taking into account the presence of a high 
degree  of  skewness  in  the  distribution.  Nixon  and  Thompson  [11]  developed  Bayesian  methods 
whereby costs and effects are considered jointly, and allowed for the typically skewed distribution of 
cost data by using Gamma distributions. Manca et al. [12] also included covariates in a multilevel 
framework for multicentre studies. 
One of the aims of regression models in CEA is to infer causal relationships between a dependent 
variable (cost or effectiveness) and the variable of interest (e.g., medical treatment). Other variables, 
known as control variables, are included to minimize the bias and uncertainty of the estimation when 
there  are  differences  in  the  baseline  characteristics  of  the  treatment  groups,  as  usually  occurs  in 
observational studies. Conditional on the model, estimates of these coefficients may be unbiased, but 
in the usual situation in which the single model selected is wrong, then estimates will be biased. 
However,  most  studies  in  this  field  omit  from  their  analysis  the  selection  of  variables  that  are 
explanatory of treatment outcomes.  The use of a single model may ignore the question of model 
uncertainty and thus lead to underestimation of the uncertainty concerning quantities of interest. In 
fact, the full model, including all control variables, would have a poorer predictive capacity than the 
true  model  when  some  of  the  covariate  effects  are  zero.  In  this  case,  the  uncertainty  about  the 
prediction may also be overestimated. 
In this paper, we examine different methods for variable selection from a Bayesian perspective. The 
Bayesian  approach  to  model  selection  and  to  accounting  for  model  uncertainty  overcomes  the 
difficulties encountered with the classical approach, based on p-values. Bayesian estimation expresses 
all uncertainty, including uncertainty about the correct model, in terms of probability. Therefore, we 
can directly estimate the subsequent  probability of a model, or the probability that  a covariate is 
included  in  the  real  model.  Moreover,  the  estimation  process  for  the  Bayesian  variable  selection 
problem is, in principle, straightforward, with all results following directly from elementary probability 
theory,  the  definition  of  conditional  probability,  Bayes‘  theorem  and  the  law  of  total  
probability [13-15]. 
Raftery  et  al.  [16]  pioneered  model  selection  and  accounting  for  model  uncertainty  in  linear 
regression models. The tutorial on Bayesian Model Averaging (BMA) given by Hoeting et al. [14] 
provides a historical perspective on the combination of models and gives further references. Although 
many  papers  have  been  published  about  Bayesian  model  selection  in  applied  economic  Int. J. Environ. Res. Public Health 2010, 7                 
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models [17-21, among others], there are few examples of this methodology in the health economics 
field. Recently, Negrí n and Vá zquez-Polo [22] showed that the BMA methodology can potentially be 
used to guide the practitioner in choosing between models, and proposed the use of the Fractional 
Bayes Factor (FBF) for model comparison. In the present paper, we extend this study, to compare four 
alternative  Bayesian  procedures  for  model  selection:  the  Bayes  Information  Criterion  (BIC),  the 
Intrinsic  Bayes  Factor  (IBF),  the  Fractional  Bayes  Factor  (FBF)  and  a  novel  procedure  based  on 
intrinsic priors [23-26]. The model selection is also applied to subgroup analysis and within the net 
benefit regression framework. 
BMA  has  also  been  studied  to  account  for  uncertainty  in  non-linear  regression  models.  For 
example, Conigliani and Tancredi [27] proposed the use of Bayesian Model Averaging to model the 
distribution of costs as an average of a set of highly skewed distributions, while Jackson et al. [28] 
applied BMA in a long-term Markov model using Akaike‘s  Information Criterion (AIC) and BIC 
approximations. These authors concluded that the BIC method is more suitable when there is believed 
to be a relatively simple true model underlying the data. Jackson et al. [29] included uncertainty about 
the choice between plausible model structures for a Markov decision model, using Pseudo Marginal 
Likelihood (PML) and the Deviance Information Criterion (DIC) for model comparison. 
Bayesian  statistics  are  commonly  employed  in  the  field  of  cost-effectiveness  analysis,  with 
Spiegelhalter et al. [30] and Jones [31] being among the first to discuss the Bayesian approach for 
statistical inference in the comparison of health technologies. Since then, many studies have used the 
Bayesian approach to compare treatment options by means of cost-effectiveness analysis [32-38]. 
The rest of this paper is organized as follows. Section 2 briefly reviews the Bayesian variable 
selection  procedures,  and  presents  the  four  methods  that  are  compared  in  this  paper.  Section  3 
describes a simulation study carried out to validate the different methods. A practical application with 
real data is shown in Section 4, together with some possible applications of variable selection in the 
economic  evaluation  context.  Finally,  in  Section  5,  the  work  is  summarised  and  some  
conclusions drawn. 
2. Methodological Concepts 
2.1. Bayesian Normal Linear Regression Model 
In this paper we focus on the problem of Bayesian variable selection for linear regression models. 
Section 4 provides a brief explanation of the model considered for cost-effectiveness analysis, but we 
first present the methodological aspects involved in Bayesian  variable selection, using the general 
linear regression model defined by the equation:  
  y = X+ u, 
or equivalently:  
1 2 2, 3 3, , ... ,    1,..., , h h h k k h h y x x x u h n                (1) Int. J. Environ. Res. Public Health 2010, 7                 
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where  1 ( ,..., ,..., ) hn y y y y    is a n vector of observations of the dependent variable. The design matrix 
12 ( , ,..., ) n X x x x   ,  with  dimension  (n  k)  includes  the  exogenous  variables  in  the  sample  where 
2, , (1, ,..., ), 1,..., h h k h x x x h n   for  individual  h.  The  vector  12 ( , ,..., )
k
k        is  the  vector  of 
unknown regression coefficients, and uh is the error term which is assumed to be independent and 
normally distributed with mean 0 and variance 2. 
Assuming the above hypothesis about u‘s, the likelihood of  and 2 is given by: 
 
22 ( , ) ( , ), n y N X I    
         
      (2) 
where In denotes the n n identity matrix. 
The usual choice of prior distribution parameter in the context of linear regression models is the 
conjugate normal-inverse-gamma prior [15]. The normal–inverse-gamma distribution is adopted as the 
prior distribution for the vector coefficient () and variance term (2): 
 
2 2 ( 2)/2 0 1 0 2 ( , ) ( ) exp[ [( ) ( ) ]/(2 )],
dk Va         
            (3) 
with hyperparameters 0, V1, a and d. 
Combining  likelihood  and  prior  distribution  through  Bayes‘  theorem,  we  obtain  the  posterior 
distribution of  and . This posterior is also normal–inverse-gamma, as shown in [39]: 
 
2 2 ( 2 )/2 * * 1 * * 2 ( , , ) ( ) exp[ [( )( ) ( ) ]/(2 )],
d k n y X V a         
              (4) 
where: 
 
* 1 1 ( ) , V V XX
    
 
* 1 1 1 0 ( ) ( ), V XX V Xy 
        
 
* 0 1 0 * 1 * ( ) ( ) . a a V yy V    
         
The marginal posterior distribution of  is obtained by integrating out  using the integration from 
Equation (4). Therefore, we have: 
 
* * * 1 * 2 ( , ) [1 ( ) ( ) ( )] ,
d k n
y X a V      

        
which is a Student tdistribution with d+n degrees of freedom and hyperparameters *, a* and V*, with 
mean and variance–covariance matrix given by 
*   and 
   
a
*
d  n 2
V
*, respectively. 
Using conjugacy properties, it can be obtained directly that the condition al distribution of 2 given 
 is an inverse-gamma, IG(A,B), with parameters: 
 
* * 1 * * ( )( ) ( ) , A V a    
       
  B d k n    . 
2.2. Bayes Factors and Posterior Model Probabilities 
Suppose that we are comparing q models for data x: 
  : ( ),    1,..., , i i   M X f x i q    Int. J. Environ. Res. Public Health 2010, 7                 
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where  i  is  an  unknown  parameter.  Assume,  moreover,  that  we  have  prior  distributions, 
( ),   1,..., , ii iq    for the unknown parameters, and consider the marginal densities of  x : 
  ( ) ( ) ( ) . i i i i i i m x f x d       
The Bayes factor for comparing models Mj and Mi is given by: 
 
( ) ( ) ()
.
() ( ) ( )
j j j j j j
ji
i i i i i i
f x d mx
B
mx f x d
   
   
 
   
      (5) 
The Bayes factor is often interpreted as the ―odds provided by the data for Mj over Mi‖. Thus Bji=5 
would suggest that the data favour Mj over Mi at odds of 5 to one. Alternatively, Bji is sometimes 
called the ―weighted likelihood ratio of Mj to Mi‖, with the priors being the ―weighting functions‖. 
From Equations (2) and (3), it follows that the Bayes factor in favour of model j versus model i for 
linear models has the expression: 
 
1/2 ( )/2 1/2 * *
1/2 1/2 * * .
dn
ij i
ji
j ji
VV a
B
a VV


  

  (6) 
If prior probabilities of the models,  ( ),   1,..., , i M i q    are available, then one can compute the 
posterior probabilities of the models as: 
 
1
1
1
() ( ) ( )
( | ) .
() ( ) ( )
q
j ii
i ji q
j i
jj
j
M M m x
M x B
M M m x
 

 




   
 

  (7) 
For a uniform prior on the models, 
1
( ) ,   1,..., , i M i q
q
  expression (7) becomes: 
 
   
(Mi | x) 
1
Bji
j1
q


mi(x)
mj(x)
j1
q

.  (8) 
where    (Mi | x)represents the posterior probability of model i. Using this posterior probability, we can 
observe the models with the highest probabilities or compute the probability of inclusion of a covariate 
as the sum of the posterior probabilities of all the models that include this covariate.  
2.3. Objective Bayesian Methods and Model Selection 
Observe that the variable selection problem is by its nature a model selection problem, in which we 
must choose one model from among 2k possible submodels of the above full one (1). It is common to 
set  1 0    to include the intercept in any model. In this case the number of possible submodels is 2k1. 
A model containing no regressors but only the intercept is denoted as  M
1, and a model containing i 
regressors, i k, is denoted as M
i . There are 
k
i



 models M
i and for each one there is a specific data Int. J. Environ. Res. Public Health 2010, 7                 
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set and a design matrix. Note that any model is nested within the full model and that the intercept-only 
model M
1 is nested within any model M
i.  
As shown in the previous section, Bayesian analysis permits the inclusion of prior information 
about  the  parameters.  However,  the  use  of  prior  information  becomes  problematic  for  variable 
selection. A model with k  covariates requires the elicitation of 2k submodels that include from zero to 
k covariates, that is, k2
k1 coefficients must be elicited. Partial solutions such as eliciting only the 
coefficients for the full model, using these prior distributions for the remaining models, are not 
appropriate because the meaning of common parameters can change from one model to another. 
A possible solution is to carry out a Bayesian analysis assuming noninformative prior distributions. 
However, it is well known that the use of improper noninformative priors is not possible in model 
selection. Indeed, let us assume that a conventional improper prior is used for a generic model Mi,  
 (,
2) 
2. 
This improper prior is equivalent to the prior distribution in Expression (3), setting V
−1 = 0, a = 0 
and d = −k. The Bayes factor, Bji given by equation (6) is not well-defined for improper priors because 
of the terms |Vi|
1/2 and |Vj|
1/2, both of which are infinite. 
Alternative  procedures  for  variable  selection  have  recently  been  developed.  In  this  paper,  we 
compare four of these procedures: Bayesian Information Criterion (BIC), Intrinsic Bayes factor (IBF), 
Fractional Bayes factor (FBF) and the most recent technique, one that provides an objective Bayesian 
solution  based  on  intrinsic  priors  [23-26,40-41].  An  objective  Bayesian  solution  seems  to  be 
particularly suitable for this problem since little subjective prior information can be expected on the 
regression coefficient of a regressor when we do not know whether it should be included in the model. 
2.3.1. Bayesian Information Criterion (BIC) 
The BIC approximation, also known as Schwarz‘s information criterion, is a widely used tool in 
model  selection,  largely  due  to  its  computational  simplicity  and  effective  performance  in  many 
modelling  frameworks.  The  derivation  of  BIC  [42]  establishes  the  criterion  as  an  asymptotic 
approximation to a transformation of the Bayesian posterior probability of a candidate model. It has 
the advantage of simplicity and avoids the need to specify an explicit prior for each model [43-47]. 
The usual BIC for linear models has the simple expression: 
 
/2
( )/2,
ij
n
kk ii
ji
jj
ee
Bn
ee
  
 
  
  (9) 
where  ii ee   and  jj ee   are the residual sums of squares under models i and j, respectively, and  ,  ij kk  is 
the dimension of the models. 
2.3.2. Intrinsic Bayes Factor (IBF) 
The general strategy for defining the IBF starts with the definition of a proper and minimal training 
sample, which is to be viewed as a subset of the entire data  x . Because we will consider a variety of 
training samples, these are indexed by l. The standard use of a training sample to define the Bayes 
factor is to use x(l) to convert the improper i(i) into a proper posterior i(i|x(l)), and then use the Int. J. Environ. Res. Public Health 2010, 7                 
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latter to define Bayes factors for the remaining data. The result, for comparing Mj to Mi, can be seen  
to be: 
  ( ) ( ) ( ( )),
NN
ji ji ij B l B x B x l   
where:  
 
() ( ( ))
( )                and            ( ) ( ( )) ,
( ) ( ( ))
N N
j N N N N i
ji ji ij ij NN
ij
mx m x l
B B x B l B x l
m x m x l
      (10) 
are the Bayes factors that would be obtained for the full data x and training sample x(l), respectively, if 
one were to blindly use 
N
i   and 
N
j  . 
While Bji(l) no  longer  depends  on  the  arbitrary  scales  of 
N
j   and 
N
i  ,  it  does  depend  on  the 
arbitrary choice of the (minimal) training sample x(l). To eliminate this dependence and to increase 
stability, we average the Bji(l) over all possible training samples x(l), l = 1,…,L. A variety of different 
averages are possible; here we consider only the arithmetic mean IBF, defined as: 
 
mean
1
1
( ).
L
NN
ji ji ij
l
B B B l
L 
    (11) 
Different noninformative priors can be considered. Here we consider the improper reference priors 
of the form:  
 
22 ( , ) .
N
j j j j    
   
For these priors, a minimal training sample (y(l),x(l)) is a sample of size m such that all () jj XX   are 
nonsingular. Then, the Bayes factor is: 
 
( )/2 1/2
( )/2
( )/2 1/2
(( )/2) ||
.
(( )/2) ||
i
ji
j
nk
kk j N i i i i
ji nk
i j j j j
nk X X e e
B
nk X X e e




 
   
 
  (12) 
The formula of  ()
N
ij Bl  is given by the inverse of this expression replacing  , , , i j i i n X X e e   and  jj ee   
by  , ( ), ( ), ( ) i j i i m X l X l e e l   and  ( ), jj e e l   respectively.  By  using  the  above  expressions  to  calculate 
mean
ji B  we obtain the expression: 
 
( )/2 1/2 ( )/2 1/2
mean
( )/2 ( )/2 1/2 1/2
1
| ( ) ( )| ( ( )) | | ( ) 1
,
| | ( ) | ( ) ( )| ( ( ))
j i
j i
nk nk L
j j j j i i i i
ji nk nk
l j j j j i i i i
X l X l e e l X X e e
BA
L X X e e X l X l e e l
 
 

 
    
       (13) 
where: 
 
(( )/2) (( )/2)
.
(( )/2) (( )/2)
j i
ij
nk mk
A
n k m k
 

   
 
For a detailed derivation of these Bayes factors for the linear model see [40]. 
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2.3.3. Fractional Bayes Factor (FBF) 
The fractional Bayes factor [48] is based on a similar understanding to that underlying the IBF. It 
uses a proportion or fraction, b (training sample), of data to obtain an initial informative posterior 
distribution of the parameter for each model. The remaining 1b fraction of the likelihood is used for 
model discrimination. The minimal fraction is used to obtain the fractional Bayes factor, defined as the 
ratio between the minimal training sample described in 2.3.2 and n. The expression of the fractional 
Bayes factor for the linear regression model is given in [39]: 
 
(1 )/2
(( )/2) (( )/2)
.
(( )/2) (( )/2)
nb
i i i i
ji
jj jj
nb k n k e e
FBF
nb k n k ee

         
      
  (14) 
2.3.4. Bayes Factor for Intrinsic Priors 
This method is based on the use of intrinsic priors, an approach that was introduced by Berger and 
Pericchi [40] to overcome the difficulty arising with conventional priors in model selection problems. 
It has been studied by Moreno et al. [41], among others. Justifications for the use of intrinsic priors for 
model selection have been given by Berger and Pericchi [49]. Design considerations about this method 
are made in [50], and an application is shown in [24]. 
The method is described as follows. Using the definition of the matrix X defined in Section 2.1, we 
consider all sub-matrices XjX containing jregressors, for j = 1,...,k. The Bayes factor for intrinsic 
priors [50] is then computed as follows:  
 
( 1)/2 1 2 ( )/2 /2
1 2 ( 1)/2 0
2( 1) (sin ) [ ( 1)sin ]
,
( ( 1)sin )
j j n j
j n
j
j n j
Bd
nj
 


  

  

      (15) 
where 
2
()
,
j
j
y
y I H y
ns
 

1 ( ) , j j j j j H X X X X
    and 
2
y s  is the sample variance of variable y. 
The posterior probability of model Mj is given by the expression: 
 
1
1
1
Pr( | ) .
1
j
j
i
i
B
Mx
B



  (16) 
3. A Simulated Experiment 
In this section we validate the variable selection methods proposed in the previous section for linear 
regression models, using simulated data. Our aim is not to study the differences between methods in a 
wide variety of circumstances, but rather to show how the models perform and how large the posterior 
probability of inclusion must be to suggest that a variable, such as treatment, influences the outcome. 
We simulate six variables (x1, ..., x6) following the distributions described in Table 1. The first three 
variables  are simulated  from  normal distributions,  the next  two  are discrete  variables following  a 
Bernoulli process,  and the last one is distributed as a Poisson distribution. The parameters of the 
simulated  distributions  are  shown  in  Table  1.  The  dependent  variable  y  is  obtained  as  a  linear 
combination of three of them (x2, x4 and x6). The expression used to obtain y is also shown in Table 1. Int. J. Environ. Res. Public Health 2010, 7                 
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Table 1. Simulation exercise. Distribution of the variables simulated. 
Variable  Distribution  Variable  Distribution 
x1  N(= 10,= 3)  x4  Ber(p = 0.7) 
x2  N(= 5,= 1)  x5  Ber(p = 0.2) 
x3  N(= 0,= 3)  x6  P(= 4) 
2 4 6 5 3 7 4 (0,8) y x x x N          
 
We evaluate the results of the different methods for three different sample sizes n1 = 30, n2 = 100, 
n3 = 300.  For  every  method,  we  estimate  the  probability  of  all  possible  models.  To  calculate  the 
probability  of  inclusion  for  each  covariate,  we  sum  the  probabilities  of  the  different  models  that 
include this covariate. The results are shown in Tables 2, 3 and 4, respectively. 
Table 2. Bayesian variable selection. Simulation exercise (n = 30). 
Variable  BIC  IBF  FBF  Intrinsic priors 
Intercept  1  1  1  1 
x1  0.37917  0.31609  0.38295  0.43725 
x2  0.96490  0.92767  0.92733  0.94164 
x3  0.36978  0.34273  0.36931  0.42703 
x4  0.55726  0.51189  0.51474  0.55564 
x5  0.16435  0.17051  0.19437  0.25248 
x6  0.99619  0.98874  0.98653  0.99076 
Table 3. Bayesian variable selection. Simulation exercise (n = 100). 
Variable  BIC  IBF  FBF  Intrinsic priors 
Intercept  1  1  1  1 
x1  0.30080  0.29285  0.27802  0.41913 
x2  0.99876  0.99802  0.99806  0.99848 
x3  0.48868  0.47003  0.46857  0.59544 
x4  0.99975  0.99958  0.99956  0.99965 
x5  0.09133  0.08811  0.08191  0.16460 
x6  1.00000  1.00000  1.00000  1.00000 
Table 4. Bayesian variable selection. Simulation exercise (n = 300). 
Variable  BIC  IBF  FBF  Intrinsic priors 
Intercept  1  1  1  1 
x1  0.07372  0.07362  0.08469  0.12227 
x2  1.00000  1.00000  1.00000  1.00000 
x3  0.07476  0.07545  0.08584  0.12404 
x4  1.00000  1.00000  1.00000  1.00000 
x5  0.09452  0.09349  0.10848  0.15315 
x6  1.00000  1.00000  1.00000  1.00000 
 
Some conclusions can be drawn from these results. For our standard sampling model, the four 
models tested obtain very similar and accurate results. The BIC and the Bayes Factor for intrinsic Int. J. Environ. Res. Public Health 2010, 7                 
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priors seem to be slightly better than the others, providing higher probabilities of inclusion for the 
explanatory variables (x2, x4 and x6). For the smallest sample size (n1 = 30), the methods only estimate 
around  55%  of  inclusion  for  the  binary  variable x4.  As  expected,  with  large  sample  sizes  the 
probabilities  of  inclusion  for  the  relevant  covariates  are  close  to  one  and  the  results  for  the  four 
methods are very similar. 
The simulation results suggest that the probability of a true covariate being accepted depends on the 
distribution  of  the  covariate  and  the  sample  size.  With  a  small  sample  size,  covariates  with  a 
probability of inclusion greater than 50% could be judged to truly affect the outcome. However, with 
sample sizes exceeding 300, the required probability of inclusion should be more than 80%. 
As well as the probability of inclusion, using the Bayesian variable selection described in Section 2 
it is possible to estimate the posterior probability of each model. The selection of the model with the 
highest probability can lead to erroneous conclusions being drawn, because this ignores the probability 
associated with the other models. Of course, this method would be appropriate when the posterior 
probability of the best model is very high. In our simulated experiment, the true model was always 
found to be the model with the highest posterior probability for the selection model based on BIC, 
although  this  probability  varied  for  different  sample  sizes  (22.32%,  33.08%  and  77.61%,  for  the 
sample sizes 30, 100 and 300, respectively). The IBF obtains similar results to those of the BIC model. 
However, the FBF and the procedure based on intrinsic priors produce the model that includes the 
covariates x2,  x3, x4 and x6 as the most probable model for a sample size of 100, although the posterior 
probability is very similar to that obtained by the real model (32.83% vs. 32.35% for the FBF, and 
27.96% vs. 25.34% for the procedure based on intrinsic priors). 
4. Practical Application 
We  analyzed  the  usefulness  of  these  methods  for  variable  selection  with  a  real  clinical  trial, 
comparing  two  highly-active  antiretroviral  treatment  protocols  applied  to  asymptomatic  HIV  
patients  [51].  Each  treatment  combines  three  drugs  and  we  denote  them  as  control  treatment  
(d4T + 3TC + IND) and new treatment (d4T + ddl + IND). 
We obtained data on effectiveness, QALYs using EuroQol-5D [52], and on the direct costs for the 
361 patients included in the study. The QALYs were calculated as the area above/below the utility 
value. This approach to QALYs takes into account the differences in baseline utility values [53]. All 
patients  kept  a  monthly  diary  for  six  months  to  record  resource  consumption  and  quality  of  
life progress. 
As control variables we considered the age, the gender (value 0 for a male patient and value 1 for a 
female) and the existence of any concomitant illness (cc1 with a value of 1 if a concomitant illness is 
present, and 0 otherwise, and cc2 with a value of 1 if two or more concomitant illnesses are present, 
and 0 otherwise). The concomitant illnesses considered were hypertension, cardiovascular disease, 
allergies, asthma, diabetes, gastrointestinal disorders, urinary dysfunction, previous kidney pathology, 
high levels of cholesterol and/or triglycerides, chronic skin complaints and depression/anxiety. The 
time (in months) elapsed from the start of the illness until the moment of the clinical trial was also 
included in the model. Finally, the treatment was included as a dichotomous variable (T) that was Int. J. Environ. Res. Public Health 2010, 7                 
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assigned a value of 1 if the patient received the (d4T + ddl + IND) treatment protocol and a value of 0 
if the (d4T + 3TC + IND) treatment was applied. Table 5 summarizes the statistical data. 
Table 5. Statistical summary of costs, effectiveness and patient characteristics: mean and 
standard deviation (in parenthesis). 
  d4T + 3TC + IND  d4T + ddl + IND 
Effectiveness (QALYs)  0.0113899 (0.0378566)  0.0123387 (0.0347704) 
Cost (euros)  7142.44 (1573.98)  7307.26 (1720.96) 
Age (years)  35.26 (7.36)  33.95 (6.77) 
Gender (1-female, 0-male)  29%  27% 
cc1  27%  32 % 
cc2  11%  8% 
Start  79.38 (92.32)  77.54 (102.19) 
n  268  93 
 
Our  aim  is  to  explain  the  effectiveness  and  cost  as  a  function  of  the  treatment  received,  and 
controlled by covariates. The full model includes all the control variables and is given by: 
  0 1 2 3 4 5 age gender cc1 cc2 start , T E T u                        (17) 
  0 1 2 3 4 5 age gender cc1 cc2 start , T C T v                        (18) 
The joint likelihood for ,, is defined by a multivariate normal distribution: 
  ( , | , , ) (( , ), ), E C N X X        (19) 
where 
2
2 .
u uv
uv v





 
Effectiveness and cost are not independent and so we allow some correlation between the error 
terms  of  both  equations.  However,  model  selection  is  computationally  complex  when  bivariate 
distributions  are  considered  [54,55].  Posterior  probabilities  cannot  be  calculated  analytically,  and 
Markov Chain Monte Carlo (MCMC) techniques are required. For this reason, we performed Bayesian 
variable  selection  for  each  equation  separately  (assuming uv = 0).  Although  the  proposed  model 
allows for the existence of correlation between effectiveness and costs, in this practical application, as 
in many others, this correlation is low (the sample correlation is −0.0006). The final model is estimated 
assuming this correlation after calculating the probabilities of inclusion for each covariate [8,10]. 
Cost transformations, as a logarithm, are often proposed to take account of the right skewing which 
is often present. However, this transformation poses a difficulty for the interpretation of the results, 
because due to the robustness of linear methods, costs are not transformed in the presence of low levels 
of right-skewing, as has been shown by Willan et al. [8] with simulated data. Log-normal, gamma or 
other skewed distributions would be more suitable for very skewed data [11]. Selection and averaging 
between  models  with  non-normal  distributions  are  discussed  in  [27]  although  covariates  are  not 
considered  in  the  latter  paper.  Figure  1  shows  the  costs  histogram  for  each  treatment  in  our  
practical application. 
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Figure 1. Histogram of costs. 
 
The results of variable selection under the four methods and for both equations, effectiveness and 
cost, are shown in Table 6. 
Table 6. Bayesian variable selection. Real data. 
 
Only one control variable was found to have relevant explanatory power (cc2 in the effectiveness 
equation). The posterior probabilities for the other control variables were always below 30%. In this 
example, the analysis based on the full model would achieve very different conclusions from those 
obtained by the real model.  
Effectiveness  BIC  IBF  FBF  Intrinsic priors 
Intercept  1  1  1  1 
Age  0.05617  0.08066  0.09352  0.10689 
gender  0.07783  0.10726  0.12459  0.13894 
cc1  0.16203  0.21744  0.25727  0.27340 
cc2  0.86882  0.94134  0.92576  0.90300 
start  0.05350  0.07795  0.08936  0.10253 
T  0.05304  0.07403  0.08883  0.10203 
Cost  BIC  IBF  FBF  Intrinsic priors 
Intercept  1  1  1  1 
age  0.05114  0.25580  0.09651  0.06950 
gender  0.07101  0.32577  0.13125  0.09430 
cc1  0.06615  0.29938  0.12237  0.08790 
cc2  0.06134  0.28330  0.11346  0.08145 
start  0.06056  0.29493  0.11313  0.08137 
T  0.07019  0.31239  0.12952  0.09302 Int. J. Environ. Res. Public Health 2010, 7                 
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The most probable model for effectiveness includes only one control variable in the equation (cc2). 
The probability associated with this variable varies from 56.02%, for the BIC criterion, to 48.70% for 
the procedure based on intrinsic priors. 
The most probable model for cost does not include any control variables. The posterior probabilities 
of this model are 67.47% for BIC, 15.36% for IBF, 50.69% for FBF and 61.94% for the procedure 
based on intrinsic priors. Results for the most probable model are shown in Table 7. 
Table 7. Bayesian variable selection. Real data. 
Effectiveness  Mean  s.d.  95% Bayesian Interval 
Intercept  0.009151  0.004146  (0.000983, 0.0172) 
cc2  0.01989  0.01121  (−0.001929, 0.04212) 
T  0.001714  0.007757  (−0.01341, 0.01699) 
Cost  Mean  s.d.  95% Bayesian Interval 
Intercept  7142  98.52  (69481, 7334) 
T  164.1  194.1  (−215.9, 543.6) 
 
The  aim  of  a  regression  framework  applied  to  cost-effectiveness  analysis  is  to  calculate  the 
incremental effectiveness and incremental cost by estimating the coefficient of the treatment indicator 
in the effectiveness and cost equations, respectively. For this reason, we also include the treatment 
indicator in the final model. The incremental effectiveness is estimated as being 0.001714, with a 
posterior 95% Bayesian interval (−0.01341, 0.01699). The incremental cost is estimated as being 164.1 
euros, with a posterior 95% Bayesian interval (−215.9, 543.6). 
4.1. Probability of the Inclusion of the Treatment in the Regression Model 
One probability that deserves special mention is the posterior probability of the treatment. The aim 
of cost-effectiveness analysis is to estimate the incremental effectiveness and incremental cost of a 
new treatment versus the control. The inclusion of the treatment indicator in the equations of cost and 
effectiveness allows the analyst to estimate the incremental effectiveness and cost from their respective 
coefficients (T and T). In this practical application, we show that the probabilities of inclusion of the 
treatment  indicator  in  the  effectiveness  and  cost  equations  are  very  low  (0.05304  and  0.07019, 
respectively for the BIC method). The conclusion of this result is that the treatment indicator is not a 
good predictor of the effectiveness or cost, as the incremental effectiveness and cost are close to zero. 
However,  in  the  model  shown  in  Table  7, the  treatment  indicator  is  included  in  the  final  model, 
ignoring model uncertainty. From the width of the Bayesian intervals of the treatment indicator in both 
equations, we conclude that differences in incremental effectiveness and cost are not relevant between 
different treatments, and that a point estimation based on the posterior mean would be biased. 
We  can  estimate  only  the  most  probable  model,  but  in  our  example  this  model  only  has  a 
probability close to 50% and the estimation based on this model ignores the uncertainty about the other 
models. BMA [14,56,57] provides a natural Bayesian solution to estimation in the presence of model 
uncertainty.  The  estimation  of  the  coefficients  is  obtained  as  a  combination  of  the  coefficients 
estimated for each model, weighted by the posterior probability of each model. Therefore, the mean of Int. J. Environ. Res. Public Health 2010, 7                 
 
 
1590 
the incremental effectiveness (the expression is analogous for the incremental cost) is obtained by  
the expressions: 
 
1
( | ) ( | , ) Pr( | ).
q
T T j j
j
E X E M X M X 

    (20) 
An expression for the posterior variance of T is given by Leamer [58]:  
 
2
11
( | ) ( | , ) Pr( | ) ( ( | , ) ( | )) Pr( | ).
qq
T T j j T j T j
jj
V X V M X M X E M X E X M X    

       (21) 
Negrí n and Vá zquez-Polo [22] described an application of BMA in a cost-effectiveness analysis 
using  the  same  data  set.  The  estimated  incremental  effectiveness  was  0.00141,  with  a  standard 
deviation of 0.0047, for the full model and 0.00018, with a standard deviation of 0.00162, when BMA 
methodology was applied. The incremental cost was 164.3125 euros, with a standard deviation of 
196.5101, for the full model and 98.9067, with a standard deviation of 170.4027, for the BMA model. 
It is important to point out that these results are not fully comparable with those given in this paper 
because [22] included prior information on the models. 
4.2. Subgroup Analysis 
Subgroup  analysis  is  becoming  a  relevant  aspect  of  economic  evaluation  [8,11].  For  example, 
suppose that we are interested in determining whether a certain subgroup has the same incremental 
effectiveness or incremental cost as a reference subgroup. The regression model allows for subgroup 
analysis by including the interaction between the subgroup indicator and the treatment indicator. The 
existence of subgroups is studied by analyzing the statistical relevance of this interaction. Classical 
hypothesis tests have been proposed for this item, but Bayesian variable selection allows a natural 
quantity to be estimated, as this is the posterior probability of inclusion. 
As an example, suppose that we are interested in studying whether there are differences in treatment 
results  between  males  and  females.  To  analyze  the  relevance  of  the  subgroup,  we  include  the 
interaction gender T as an explanatory covariate of effectiveness and cost. 
The posterior probability of inclusion of the interaction in the effectiveness equation varies from the 
9.1844% of the BIC method to the 17.2234% of the intrinsic priors method. In view of these results, 
we cannot accept the existence of a subgroup in the effectiveness model. Analogously, the posterior 
probability of inclusion in the cost equation varies from the 19.0928% of the BIC method to the 
49.4215% of the IBF method. In this case, the probability of there being a subgroup in the cost model 
is higher, although it is always below 50%. 
It is important to recall that in conventional frequentist clinical trial protocols, it is mandatory to 
specify any intended subgroup analysis in advance, and drug regulatory agencies are very wary of 
allowing  claims  for  subgroup  effects,  because  of  the  risk  of  data  dredging  [59-61].  In  Bayesian 
analysis, the corresponding guidance should be that the prior distributions for the coefficients of these 
interaction terms must be specified to reflect genuine belief about how large such subgroup effects 
might  realistically  be,  based  on  the  existence  and  plausibility  of  appropriate  biological  
mechanisms [62]. We have shown in this subsection that Bayesian variable selection methodology can 
be used for exploratory subgroup analysis. Int. J. Environ. Res. Public Health 2010, 7                 
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4.3. Net Benefit Regression Framework 
The Net Benefit regression framework was introduced to facilitate the use of regression tools in 
economic  evaluation  [7].  Net  benefit  regression  uses  as  the  dependent  variable  the  net  benefit, 
 z  Re c, where e refers to the effectiveness, c refers to the cost and R is the ceiling ratio, which 
can be interpreted as the decision maker‘s willingness to pay for an increment in effectiveness. The 
equation should include an indicator of the treatment provided. The coefficient of this indicator is 
equal to the difference in mean net benefit for the new and control treatments. It has been shown [7,8] 
that when this difference is greater than zero then the incremental net benefit is positive and the new 
treatment is preferred. 
A difficulty with the net benefit regression framework is that the net benefit depends upon the 
decision maker‘s willingness to pay (R), a value that is not known from the cost and effect data. Thus, 
it is necessary to estimate a new equation for each value of  R considered. The variable selection 
procedures can be applied to this framework. As an example, Table 8 shows the results of the variable 
selection  with  the  intrinsic  priors  method  for  three  different  values  of  R  (R1 = 0, R2 = 50,000 and 
R3 = 100,000). As expected, the probabilities of inclusion for R = 0 coincide with the cost equation in 
Table 6. For greater values of R, the probabilities of inclusion will be more similar to those obtained 
for the effectiveness equation. 
Table 8. Bayesian variable selection with intrinsic priors. Regression Net Benefit Framework. 
Net Benefit  R = 0  R = 50,000  R = 100,000 
Intercept  1  1  1 
age  0.06950  0.09223  0.10047 
gender  0.09430  0.17929  0.17130 
cc1  0.08790  0.11447  0.17664 
cc2  0.08145  0.75767  0.89573 
start  0.08137  0.11231  0.11138 
T  0.09302  0.09378  0.09521 
5. Conclusions 
Linear regression is often used to account for the cost and effectiveness of medical treatment. The 
covariates may include sociodemographic variables, such as age, gender or race; clinical variables, 
such as initial health status, years of treatment or the existence of concomitant illnesses; and a binary 
variable  indicating  the  treatment  received.  The  coefficient  of  the  treatment  variable  for  the 
effectiveness and cost regression can be interpreted as the incremental effectiveness and incremental 
cost, respectively. Several recent studies have been made of the usefulness of including covariates in 
cost-effectiveness analysis, using approaches based on incremental cost-effectiveness or incremental 
net  benefit  [7-8,11].  These  studies  were  carried  out  in  a  frequentist  framework,  while  
Vá zquez-Polo et al. [10] developed a similar analysis from a Bayesian perspective. 
However, most studies assume only one model, usually the full one. In so doing, they ignore the 
uncertainty in model selection. In the present paper, we consider the four most important alternative 
Bayesian  variable  selection  methods  for  estimating  the  posterior  probability  of  inclusion  of  each Int. J. Environ. Res. Public Health 2010, 7                 
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covariate.  A  simulation  exercise  shows  the  performance  of  these  methods  with  linear  regression 
models, and we conclude that all of them have high and similar levels of accuracy. It has long been 
known that when sample sizes are large, the BIC criterion provides a reasonable preferred model, in 
view of its straightforward approximation procedure and the use of an implicit prior. As the four 
proposed methods in the paper do not give widely varying conclusions in the real example, the choice 
of which of these criteria to use depends on the purpose of the model assessment [28]. In our practical 
application, we considered a moderately large sample, and thus the BIC measure yielded an easily 
computable quantity with no need for computer-intensive calculations. For small sample sizes, we 
recommend the use of IBF or BF under intrinsic priors, due to the good properties presented by these 
methods: the measures are completely automatic Bayes factors, IBFs are applicable to nested as well 
as nonnested models, and they are invariant to univariate transformations of the data, among other 
advantages [40]. The Bayesian procedures for variable selection with intrinsic priors are consistent 
and, furthermore, Lindley‘s paradox (i.e., a point null hypothesis on the normal mean parameter is 
always accepted when the variance of the conjugate distribution tends to infinity) does not arise. We 
believe,  in  accordance  with  Casella  et  al.  [25]  that  ‗intrinsic  priors  provide  a  type  of  objective 
Bayesian prior for the testing problem. They seem to be among the most diffuse priors that are possible 
to use in testing, without encountering problems with indeterminate Bayes factors, which was the 
original impetus for the development of Berger and Pericchi [40]. Moreover, they do not suffer from 
―Lindley‘s paradox‖ behavior. Thus, we believe they are a very reasonable choice for experimenters 
looking for an objective Bayesian analysis with a frequentist guarantee.‘ 
All  the  Bayesian  model  selection  procedures  presented  enable  the  estimation  of  the  posterior 
probability  of  each  possible  model  and  the  probability  of  inclusion  of  each  covariate.  When  the 
posterior  probability  of  the  ―best‖  model  is  reasonably  high,  the  use  of  this  model  is  accurate. 
However, when the number of models compared is large, then the associated probability of the ―best‖ 
model might be low. In this case, the BMA strategy provides a more appropriate alternative. 
Moreover,  complementary  analyses  are  possible  with  variable  selection.  Thus,  the  incremental 
effectiveness and incremental cost may be estimated using BMA. Here, we advocate BMA analysis as 
the most coherent way to estimate the quantities of interest under model uncertainty. 
Another interesting application of variable selection is subgroup analysis. The regression model 
allows for subgroup analysis by the inclusion of the interaction between the subgroup indicator and the 
treatment indicator. The existence of subgroups is studied by analyzing the statistical relevance of this 
interaction; this is precisely the aim of variable selection. 
One difficulty with the variable selection approach is the computational burden involved when the 
number of possible regressors k is large or when interactions are considered. Then, the number of 
models becomes so large that it is impossible to compute all the posterior probabilities. In this case, we 
need to resort to a stochastic algorithm to compute only the high posterior probability model. An 
example of such an algorithm is given by Casella and Moreno [23]. This difficulty is not inherent to 
any specific variable selection procedure but is shared by all existing procedures. Int. J. Environ. Res. Public Health 2010, 7                 
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